In Our DNA SC Now Available in Every South Carolina County

A groundbreaking initiative out of the Medical University of South Carolina (MUSC) demonstrates the viability of large-scale genomic screening programs that transcend traditional healthcare boundaries. The study, recently published in JAMA Network Open, reveals how over 50,000 South Carolinians across all 46 counties—including those in medically underserved rural areas—have undergone no-cost genetic screening through the community-centric “In Our DNA SC” project. This extensive participation marks a significant advance in population-wide genomic equity.

Unlike conventional genetic tests aimed at patients with existing conditions or known family histories, this program proactively identifies genetic variations linked to serious but preventable diseases before symptoms manifest. The targeted conditions include hereditary breast and ovarian cancer syndrome, Lynch syndrome, and familial hypercholesterolemia—each known to dramatically elevate cancer or cardiovascular disease risks yet are amendable to early interventions.

The program’s design capitalizes on flexible sampling options such as blood draws at MUSC clinics, community-based specimen collection events, and remote testing via at-home cheek swabs. By minimizing logistical barriers and partnering with grassroots organizations, the researchers engineered a model grounded in implementation science principles that successfully penetrated rural and socially vulnerable demographics.

Epidemiologically, about one in every 65 screened individuals carries a pathogenic variant linked to one of the three diseases. Identified participants are promptly offered genetic counseling to interpret findings and facilitate tailored preventive care, including earlier cancer screenings or cholesterol management pharmacotherapy. Beyond individual care, anonymized data feeds an evolving database for refining precision medicine strategies.

Importantly, the study confirms equitable reach across geographic and socioeconomic divides, verified by adjusting participation rates against county population sizes, rurality metrics, and Centers for Disease Control and Prevention social vulnerability indices. However, it also highlights continued opportunities to boost engagement in the most remote communities.

“The ability to extend genomic screening outside academic medical centers and into diverse, rural populations is a pivotal step toward health equity,” explained Dr. Kalyani Sonawane, MUSC’s assistant director of data science and analytics. Dr. Daniel Judge, principal investigator and director of MUSC’s Cardiovascular Genetics Program, emphasized the life-saving potential, noting that early detection empowers preventative interventions that could reduce South Carolina’s leading causes of death—cancer and heart disease.

This pioneering research underscores the necessity of cultivating trust through community partnerships and educational outreach to mitigate apprehensions about genetic risk information. Looking ahead, the MUSC team plans to evaluate the long-term health outcomes of those screened, assessing the program’s efficacy in translating genomic insights into tangible reductions in disease burden.

As population-wide genomic screening gains momentum, initiatives like In Our DNA SC illuminate pathways for integrating genetic medicine into public health, promising a future where inherited risks are no longer a silent threat but a call to proactive care.